Physician profile
Michael A Love
NPI 1093789273
$4,126.08
in general payments reported to CMS, 2019-2025
26 companies · $32.90 in 2025
The $32.90 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,501 · 2020: $826 · 2021: $754 · 2022: $469 · 2023: $401 · 2024: $142 · 2025: $32.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,221.90 | 2020-2025 | Aveir, Jot Dx, Assurity |
| Novartis Pharmaceuticals Corporation | $479.80 | 2019-2021 | |
| Pfizer INC. | $315.03 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $288.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $277.88 | 2019-2021 | |
| Amgen INC. | $193.30 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $189.57 | 2019 | |
| Amarin Pharma, INC. | $176.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $175.58 | 2019-2021 | |
| Medtronic, INC. | $136.46 | 2023 | Linq II, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $104.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $85.54 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $70.69 | 2019-2021 | |
| Esperion Therapeutics, INC. | $61.20 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $59.38 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $58.25 | 2019-2020 | |
| Astellas Pharma US INC | $44.98 | 2019-2020 | |
| Cardiva Medical, INC. | $40.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.38 | 2020-2021 | |
| Vifor Pharma, INC. | $18.76 | 2020 | |
| Akcea Therapeutics, INC. | $18.57 | 2020 | |
| Daiichi Sankyo INC. | $17.13 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $15.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.11 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.